TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures

Telix Pharmaceuticals faces a class action lawsuit alleging misleading statements about drug development and manufacturing capabilities, resulting in a 21% stock drop after receiving an SEC subpoena and FDA Complete Response Letter.

Insights
TLX   negative

Company experienced significant stock decline due to alleged regulatory failures, misleading disclosures about drug development progress, and manufacturing compliance issues